Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The company operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages; and NAV4694, a fluorine-18 labeled positron emission tomography imaging agent for use as an aid in the imaging and evaluation of patients with signs or symptoms of Alzheimers disease and mild cognitive impairment. It is also developing NAV5001, an iodine-123 labeled single photon emission computed tomography imaging agent that is used as an aid in the diagnosis of Parkinson's disease and other movement disorders with potential use as a diagnostic aid in dementia; diagnostic substances, including technetium 99m tilmanocept and other diagnostic applications of its Manocept platform; and therapeutic development programs, such as therapeutic applications of its Manocept platform, as well as various development programs. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was founded in 1983 and is headquartered in Dublin, Ohio.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryHealth Care Equipment
SectorMedical
Phone+1-614-7937500
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees19
Next Earnings Date3/14/2019 (Estimated)
OptionableOptionable
Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB) Frequently Asked Questions
What is Navidea Biopharmaceuticals' stock symbol?
Navidea Biopharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "NAVB."
How were Navidea Biopharmaceuticals' earnings last quarter?
Navidea Biopharmaceuticals Inc (NYSEAMERICAN:NAVB) issued its quarterly earnings data on Wednesday, August, 8th. The biopharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter. The biopharmaceutical company earned $0.54 million during the quarter. View Navidea Biopharmaceuticals' Earnings History.
When is Navidea Biopharmaceuticals' next earnings date?
Has Navidea Biopharmaceuticals been receiving favorable news coverage?
News stories about NAVB stock have trended somewhat positive recently, InfoTrie Sentiment reports. The research firm identifies positive and negative news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Navidea Biopharmaceuticals earned a daily sentiment score of 1.7 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 4.0 out of 10, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near future.
Are investors shorting Navidea Biopharmaceuticals?
Navidea Biopharmaceuticals saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 8,860,498 shares, an increase of 16.0% from the January 15th total of 7,639,128 shares. Based on an average daily trading volume, of 503,692 shares, the days-to-cover ratio is presently 17.6 days. Currently, 5.8% of the shares of the company are short sold. View Navidea Biopharmaceuticals' Current Options Chain.
Who are some of Navidea Biopharmaceuticals' key competitors?
Some companies that are related to Navidea Biopharmaceuticals include Pfenex (PFNX), Neuren Pharmaceuticals (NEU), Matinas Biopharma (MTNB), Matinas BioPharma (MTNB), Covalon Technologies (COV), Equillium (EQ), Immutep (IMM), Medicure (MPH), Bionomics (BNO), Acasti Pharma (ACST), IntelGenx Technologies (IGX), Botanix Pharmaceuticals (BOT), CEL-SCI (CVM), Orgenesis (ORGS) and Promis Neurosciences (PMN).
What other stocks do shareholders of Navidea Biopharmaceuticals own?
Who are Navidea Biopharmaceuticals' key executives?
Navidea Biopharmaceuticals' management team includes the folowing people:
- Mr. Jed A. Latkin, CEO, COO, CFO, Sec., Treasurer & Director (Age 45)
- Mr. William J. Regan, Chief Compliance Officer (Age 67)
- Ms. Sharon Correia, Sr. Director of Corp. Communications
- Dr. Michael Stanley Rosol Ph.D., Chief Medical Officer
How do I buy shares of Navidea Biopharmaceuticals?
Shares of NAVB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Navidea Biopharmaceuticals' stock price today?
One share of NAVB stock can currently be purchased for approximately $0.1660.
How big of a company is Navidea Biopharmaceuticals?
Navidea Biopharmaceuticals has a market capitalization of $30.19 million. Navidea Biopharmaceuticals employs 19 workers across the globe.
What is Navidea Biopharmaceuticals' official website?
How can I contact Navidea Biopharmaceuticals?
Navidea Biopharmaceuticals' mailing address is 4995 Bradenton Ave Ste 240, DUBLIN, OH 43017-3552, United States. The biopharmaceutical company can be reached via phone at +1-614-7937500.
MarketBeat Community Rating for Navidea Biopharmaceuticals (NYSEAMERICAN NAVB)
MarketBeat's community ratings are surveys of what our community members think about Navidea Biopharmaceuticals and other stocks. Vote "Outperform" if you believe NAVB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NAVB will underperform the S&P 500 over the long term. You may vote once every thirty days.
